Results
Title

Rosiglitazone enhances neovascularization in diabetic rat ischemic hindlimb model.

Authors

Majid Khazaei; Ensieh Salehi

Abstract

Background. There is increasing evidence that peroxisome proliferator--activated receptors (PPARs) may be involved in the regulation of angiogenesis. In this study, we examined whether rosiglitazone, a PPARγ agonist, can restore angiogenesis in a rat hindlimb ischemia model of diabetes. Methods. Male wistar rats were divided into four groups (n=6 each): control, diabetic and control and diabetic rats who received rosiglitazone (8 mg/kg/day). Diabetes was induced by streptozotocin (55 mg/kg; ip). After 21 days, serum concentrations of nitric oxide (NO), vascular endothelial growth factor (VEGF) and soluble VEGF receptor-2 (VEGFR-2) were measured and neovascularization in ischemic legs was evaluated by immunohistochemistry. Results. Capillary density and capillary/fiber ratio in hindlimb ischemia of diabetic animals were significantly lower than the control group (P<0.05). Rosiglitazone significantly restored neovascularization in diabetic animals (P<0.05).Conclusions. rosiglitazone enhances neovascularization in diabetic ischemic skeletal muscle and could be considered for treatment of peripheral artery disease in diabetic subjects.

Subjects

ROSIGLITAZONE; NEOVASCULARIZATION; HINDLIMB; PEROXISOME proliferator-activated receptors; VASCULAR endothelial growth factor receptors; LABORATORY rats; STREPTOZOTOCIN

Publication

Biomedical Papers of the Medical Faculty of Palacky University in Olomouc, 2012, Vol 156, Issue 4, p312

ISSN

1213-8118

Publication type

Academic Journal

DOI

10.5507/bp.2012.052